Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Homie Razavi(Center for Disease Analysis), Ching‐Chih Hu(Keelung Chang Gung Memorial Hospital), Joaquín Cabezas(Instituto de Investigación Marqués de Valdecilla), Tarik Asselah(Inserm), Wan‐Long Chuang(Kaohsiung Medical University), Myeong-Eun Cheon(Korea Disease Control and Prevention Agency), Paulo Roberto Abrão Ferreira(Universidade Federal de São Paulo), Norah A. Terrault(University of California, San Francisco), Hugo Cheinquer(Universidade Federal do Rio Grande do Sul), Javier Crespo(Marqués de Valdecilla University Hospital), Abdulrahman Aljumah, Yao‐Chun Hsu(China Medical University), Ivane Gamkrelidze, Junko Tanaka(Hiroshima University), Mia J. Biondi(York University), Robert G. Gish(Hepatitis B Foundation), Xavier Forns(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Maria Lúcia Gomes Ferraz(Universidade Federal de São Paulo), Ohad Etzion(Ben-Gurion University of the Negev), Soo Aleman(Karolinska University Hospital), Stefan Zeuzem(Goethe University Frankfurt), Victor de Lédinghen(Université de Bordeaux), Marı́a Buti(Vall d'Hebron Hospital Universitari), Pei‐Jer Chen(National Taiwan University Hospital), Javier García‐Samaniego(Instituto de Salud Carlos III), Alessio Aghemo, Saad Alghamdi(Umm al-Qura University), Graham R. Foster(Queen Mary University of London), Nicola Coppola(University of Campania "Luigi Vanvitelli"), Sarah Blach(Center for Disease Analysis), Ziv Ben‐Ari, Julian Hercun(National Institutes of Health), N. Masri, Maurizia Rossana Brunetto(Azienda Ospedaliera Universitaria Pisana), Thomas Berg(University Hospital Leipzig), Ulus Salih Akarca(Ege University), Carla S. Coffin(University of Calgary), Cihan Yurdaydın(Ankara University), Jeffrey S. Glenn(Stanford Medicine), Antonio Craxı̀(University of Palermo), Abdullah S Alghamdi(King Fahad Hospital Jeddah), Pierre M. Gholam(University School), Liliana Gheorghe(Carol Davila University of Medicine and Pharmacy), Ann‐Sofi Duberg(Örebro University), Wornei Silva Miranda Braga, Ibrahim Altraif, Abduljaleel Alalwan, Giovanni Battista Gaeta, Waleed K. Al‐Hamoudi, Carlos Eduardo Brandão‐Mello(Universidade Federal do Estado do Rio de Janeiro)
Cited by 61
Related Papers
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877